WO2002028481A3 - Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies - Google Patents

Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies Download PDF

Info

Publication number
WO2002028481A3
WO2002028481A3 PCT/US2001/030963 US0130963W WO0228481A3 WO 2002028481 A3 WO2002028481 A3 WO 2002028481A3 US 0130963 W US0130963 W US 0130963W WO 0228481 A3 WO0228481 A3 WO 0228481A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
antibody
cell
methods
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/030963
Other languages
French (fr)
Other versions
WO2002028481A2 (en
WO2002028481A9 (en
Inventor
Keting Chu
Lorianne Masuoka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE60119945T priority Critical patent/DE60119945T2/en
Priority to JP2002532304A priority patent/JP4202127B2/en
Priority to AU2001296547A priority patent/AU2001296547A1/en
Priority to CA002424749A priority patent/CA2424749A1/en
Priority to EP01977428A priority patent/EP1322383B9/en
Priority to US10/380,223 priority patent/US7288252B2/en
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of WO2002028481A2 publication Critical patent/WO2002028481A2/en
Publication of WO2002028481A3 publication Critical patent/WO2002028481A3/en
Anticipated expiration legal-status Critical
Publication of WO2002028481A9 publication Critical patent/WO2002028481A9/en
Priority to US11/849,107 priority patent/US7445780B2/en
Priority to US12/246,029 priority patent/US7611708B2/en
Priority to US12/568,373 priority patent/US7820170B2/en
Priority to US12/891,415 priority patent/US8088383B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.
PCT/US2001/030963 2000-10-02 2001-10-02 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies Ceased WO2002028481A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DE60119945T DE60119945T2 (en) 2000-10-02 2001-10-02 METHOD FOR THE THERAPY OF B-CELL MALIGNITIES USING ANTAGONISTIC ANTI-CD40 antibodies
JP2002532304A JP4202127B2 (en) 2000-10-02 2001-10-02 B cell malignancy treatment method using antagonist anti-CD40 antibody
AU2001296547A AU2001296547A1 (en) 2000-10-02 2001-10-02 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
CA002424749A CA2424749A1 (en) 2000-10-02 2001-10-02 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
EP01977428A EP1322383B9 (en) 2000-10-02 2001-10-02 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
US10/380,223 US7288252B2 (en) 2000-10-02 2001-10-02 Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies
US11/849,107 US7445780B2 (en) 2000-10-02 2007-08-31 Antagonistic anti-CD40 antibodies
US12/246,029 US7611708B2 (en) 2000-10-02 2008-10-06 Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies
US12/568,373 US7820170B2 (en) 2000-10-02 2009-09-28 Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies
US12/891,415 US8088383B2 (en) 2000-10-02 2010-09-27 Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23755600P 2000-10-02 2000-10-02
US60/237,556 2000-10-02

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10380223 A-371-Of-International 2001-10-02
US11/849,107 Continuation US7445780B2 (en) 2000-10-02 2007-08-31 Antagonistic anti-CD40 antibodies

Publications (3)

Publication Number Publication Date
WO2002028481A2 WO2002028481A2 (en) 2002-04-11
WO2002028481A3 true WO2002028481A3 (en) 2003-03-06
WO2002028481A9 WO2002028481A9 (en) 2003-07-03

Family

ID=22894238

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2001/030859 Ceased WO2002028905A2 (en) 2000-10-02 2001-10-02 Human anti-cd40 antibodies
PCT/US2001/030963 Ceased WO2002028481A2 (en) 2000-10-02 2001-10-02 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
PCT/US2001/030857 Ceased WO2002028904A2 (en) 2000-10-02 2001-10-02 Human anti-cd40 antibodies
PCT/US2001/030961 Ceased WO2002028480A2 (en) 2000-10-02 2001-10-02 Methods of therapy for b-cell malignancies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2001/030859 Ceased WO2002028905A2 (en) 2000-10-02 2001-10-02 Human anti-cd40 antibodies

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US2001/030857 Ceased WO2002028904A2 (en) 2000-10-02 2001-10-02 Human anti-cd40 antibodies
PCT/US2001/030961 Ceased WO2002028480A2 (en) 2000-10-02 2001-10-02 Methods of therapy for b-cell malignancies

Country Status (10)

Country Link
US (5) US7288252B2 (en)
EP (3) EP1717251B1 (en)
JP (6) JP4271440B2 (en)
AT (3) ATE541860T1 (en)
AU (4) AU2001296507A1 (en)
CA (2) CA2424749A1 (en)
DE (2) DE60119945T2 (en)
ES (1) ES2357051T3 (en)
PT (1) PT1326896E (en)
WO (4) WO2002028905A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12274747B2 (en) 2021-01-28 2025-04-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
US12465029B2 (en) 2014-12-10 2025-11-11 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
WO2002028905A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Human anti-cd40 antibodies
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP2011802A3 (en) 2001-04-27 2009-04-15 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
CA2544364A1 (en) * 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
WO2005044307A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for b cell-related cancers
ES2346978T3 (en) * 2003-11-04 2010-10-22 Novartis Vaccines And Diagnostics, Inc. USE OF ANTI-CD40 ANTIGONIST MONOCLONANT ANTIBODIES FOR THE TREATMENT OF MULTIPLE MYELOMA.
SI1680141T1 (en) * 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
JP4746552B2 (en) * 2003-11-04 2011-08-10 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Use of antagonist anti-CD40 antibodies for the treatment of autoimmune and inflammatory diseases and organ transplant rejection
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
US20070292439A1 (en) * 2004-04-27 2007-12-20 Novartis Vaccines And Diagnostics, Inc. Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
AU2006235695B2 (en) 2005-04-09 2011-10-13 Fusion Antibodies Limited Cathepsin S antibody
PL1889065T3 (en) 2005-05-18 2013-12-31 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
JP5208730B2 (en) * 2005-05-18 2013-06-12 ノバルティス アーゲー Methods for the diagnosis and treatment of proliferative disorders mediated by CD40 signaling
JP2009517339A (en) * 2005-11-01 2009-04-30 ノバルティス アーゲー Use of anti-CD40 antibodies
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
GEP20125628B (en) 2006-04-21 2012-09-10 Novartis Ag Pharmaceutical compositions containing antagonist anti-cd40 antibody
EP2589654A1 (en) 2006-05-03 2013-05-08 The Regents of the University of Colorado, a body corporate CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
CN101970003A (en) * 2007-11-09 2011-02-09 诺华有限公司 Uses of anti-cd40 antibodies
EP2245065A1 (en) 2008-01-23 2010-11-03 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
US8518410B2 (en) 2009-03-10 2013-08-27 Baylor Research Institute Fusion protein with HIV antigen
EP2406288B1 (en) 2009-03-10 2016-12-14 Baylor Research Institute Antigen presenting cell targeted vaccines
AU2010222942B2 (en) 2009-03-10 2013-01-10 Baylor Research Institute Anti-CD40 antibodies and uses thereof
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AR083847A1 (en) 2010-11-15 2013-03-27 Novartis Ag FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
PT2683406T (en) 2011-03-11 2019-07-08 Beth Israel Deaconess Medical Ct Inc ANTI-CD40 ANTIBODIES AND USE OF THEM
TW201300418A (en) 2011-03-25 2013-01-01 Baylor Res Inst Compositions and methods to immunize against hepatitis C virus
US9475879B2 (en) * 2011-04-21 2016-10-25 Bristol-Myers Squibb Company Antibody polypeptides that antagonize CD40
TR201904882T4 (en) * 2011-11-17 2019-05-21 Gundram Jung Bispecific antibodies for medical use.
JP2016011258A (en) * 2012-10-26 2016-01-21 株式会社ペルセウスプロテオミクス Anti-human CD40 monoclonal antibody and use thereof
JP6475631B2 (en) 2012-11-19 2019-02-27 バリオファルム・アクチェンゲゼルシャフト Recombinant bispecific antibody that binds to CD20 and CD95
EP3094652B1 (en) 2014-01-13 2021-09-29 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
HUE054075T2 (en) 2014-10-29 2021-08-30 Seagen Inc Dosage and administration of non-fucosylated anti-cd40 antibodies
RU2715597C2 (en) 2015-05-29 2020-03-02 Эббви Инк. Antibodies to cd40 and methods of use thereof
HUE056769T2 (en) 2015-09-04 2022-03-28 Primatope Therapeutics Inc Humanized anti-cd40 antibodies and uses thereof
BR112018006360A2 (en) * 2015-09-30 2018-10-09 Janssen Biotech Inc agonistic antibodies that specifically bind to human cd40 and methods of use
PL3468997T3 (en) 2016-06-08 2024-12-16 Xencor, Inc. Treatment of IgG4-related diseases with anti-CD19 antibodies that cross-link to CD32b
JP7461741B2 (en) 2016-06-20 2024-04-04 カイマブ・リミテッド Anti-PD-L1 and IL-2 Cytokines
UA128304C2 (en) 2016-07-14 2024-06-05 Ґенмаб А/С MULTISPECIFIC ANTIBODY TO CD40 AND CD137
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US11525005B2 (en) 2017-06-01 2022-12-13 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
IL272159B2 (en) 2017-08-04 2026-03-01 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
CN108503708B (en) * 2017-09-01 2021-07-30 北京智仁美博生物科技有限公司 Anti-human CD47 antibody and use thereof
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
MA52889A (en) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc INCREASED IMMUNE ACTIVITY BY MODULATION OF POST-CELLULAR SIGNALING FACTORS
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20210355216A1 (en) 2018-10-05 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and systems for controlling the agonistic properties of antibody variable domains by light
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
BR112021009835A2 (en) 2018-11-30 2021-08-17 Jiangsu Hengrui Medicine Co., Ltd. anti-cd40 antibody, antigen-binding fragment and pharmaceutical use thereof
MX2021006360A (en) 2018-11-30 2021-08-11 Jiangsu Hengrui Medicine Co Cd40 antibody pharmaceutical composition and use thereof.
EP3917960A1 (en) * 2019-02-01 2021-12-08 LAVA Therapeutics N.V. Novel cd40-binding antibodies
NL2022494B1 (en) * 2019-02-01 2020-08-19 Lava Therapeutics B V Novel CD40-binding antibodies
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
EP4069291A1 (en) 2019-12-03 2022-10-12 Evotec International GmbH Interferon-associated antigen binding proteins and uses thereof
CN121197633A (en) 2019-12-13 2025-12-26 比特比德科有限责任公司 Ingestible device for delivering therapeutic agents to the gastrointestinal tract
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
EP4305066A1 (en) 2021-03-09 2024-01-17 Genmab A/S Multispecific binding agents against cd40 and cd137 in therapy
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
GB2623267A (en) 2021-05-07 2024-04-10 Redkik Oy Risk probability assessment for cargo shipment operations and methods of use thereof
EP4365200A4 (en) * 2021-06-28 2025-04-09 Jiangsu Hengrui Pharmaceuticals Co., Ltd. ANTI-CD40 ANTIBODY, ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE
KR20240026507A (en) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. Immune cells engineered to promote thananotransmission and uses thereof
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
EP4393937A4 (en) 2021-08-26 2025-12-31 Duality Biologics Shanghai Co Ltd STERODIC COMPOUND AND CONJUGATE OF IT
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
WO2023198851A1 (en) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
CN120302979A (en) 2022-12-01 2025-07-11 生物技术公司 Combination therapy of multispecific antibodies targeting CD40 and CD137 with anti-PD1 Ab and chemotherapy
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034096A1 (en) * 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US59427A (en) * 1866-11-06 Improvement in fences
US142358A (en) * 1873-09-02 Improvement in the purification of illuminating-gas
US4355023A (en) * 1980-09-30 1982-10-19 The Massachusetts General Hospital Antibody fragment compositions and process
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4689299A (en) * 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4727018A (en) * 1984-05-18 1988-02-23 Eichner Ronald D Immunoregulation of transplantable tissue
US5068223A (en) * 1985-09-09 1991-11-26 Board Of Regents, University Of Texas System Hydrophobic peptide esters and amides
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
US4923872A (en) * 1986-08-26 1990-05-08 Warner-Lambert Co. Analogues of pyrrolo[3,2d]pyrimidin-4-ones
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
DE3773893D1 (en) * 1987-01-17 1991-11-21 Asta Pharma Ag SYNERGISTIC COMBINATION OF AZELASTINE AND THEOPHYLLIN OR AZELASTINE AND BETA MIMETIC.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
EP0434879A1 (en) 1989-12-14 1991-07-03 Schering-Plough Method of making factor dependent human B cell lines
CA2086325C (en) 1990-07-02 2010-10-05 Peter S. Linsley Ligand for cd28 receptor on b cells and methods
KR100283541B1 (en) 1991-10-25 2001-03-02 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 New cytokines
JP4157160B2 (en) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド Methods for the preparation of modified antibody variable regions
IL104684A0 (en) 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
WO1994001457A1 (en) 1992-07-07 1994-01-20 Fish Eleanor N Interferon receptor binding peptides
DE69334064T2 (en) * 1992-07-09 2007-05-24 Novartis Vaccines and Diagnostics, Inc., Emeryville Antagonist monoclonal antibodies to human CD40
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
WO1994004570A1 (en) 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
DE614989T1 (en) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Method for in vivo selection of ligand binding proteins.
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
KR960704576A (en) 1993-10-01 1996-10-09 크리스토퍼 엘. 와이트 Antibodies to CD40
DE69433820T2 (en) * 1993-12-23 2005-06-23 Immunex Corp., Seattle USE OF SOLUBLE OLIGOMERIC CD40 LIGANDS OR MONOCLONAL ANTIBODIES FOR THE MANUFACTURE OF A MEDICINE FOR PREVENTING OR TREATING NEOPLASTIC DISEASES
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
JP2003508016A (en) 1999-04-16 2003-03-04 エフ．ホフマン−ラ ロシュ アーゲー Nucleic acids encoding CD40 / CD40L chimeric polypeptides, methods for their production and uses thereof
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
DE60035057T2 (en) * 1999-10-04 2008-01-31 Novartis Vaccines and Diagnostics, Inc., Emeryville CD40 antagonist for the treatment of psoriasis
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU1590201A (en) 1999-11-09 2001-06-06 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
AU2001259215A1 (en) * 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
WO2002028905A2 (en) * 2000-10-02 2002-04-11 Chiron Corporation Human anti-cd40 antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034096A1 (en) * 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. LONGO ET AL: "Inhibition of human B-cell lymphoma growth by soluble recombinant human CD40 ligand (Meeting abstract).", THE FASEB JOURNAL, vol. 9, no. 3, 1995, Bethesda, MD, USA, pages A205, XP002215207 *
P. KARLSSON ET AL.: "Selection of human single chain antibodies against CD40.", IMMUNOLOGY LETTERS, vol. 73, no. 2-3, September 2000 (2000-09-01), Amsterdam, The Netherlands, pages 161, XP001073504 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12465029B2 (en) 2014-12-10 2025-11-11 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
US12274747B2 (en) 2021-01-28 2025-04-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome

Also Published As

Publication number Publication date
WO2002028480A3 (en) 2002-07-11
AU2001296507A1 (en) 2002-04-15
WO2002028905A2 (en) 2002-04-11
JP2004510752A (en) 2004-04-08
EP1717251B1 (en) 2012-01-18
ATE489403T1 (en) 2010-12-15
JP2009201523A (en) 2009-09-10
JP2008156339A (en) 2008-07-10
US20090081242A1 (en) 2009-03-26
JP4202127B2 (en) 2008-12-24
AU2001296547A1 (en) 2002-04-15
US7288252B2 (en) 2007-10-30
DE60119945T2 (en) 2007-01-18
JP2004517611A (en) 2004-06-17
EP1717251A2 (en) 2006-11-02
WO2002028481A2 (en) 2002-04-11
ATE327004T1 (en) 2006-06-15
US7820170B2 (en) 2010-10-26
JP4271440B2 (en) 2009-06-03
CA2424749A1 (en) 2002-04-11
WO2002028904A2 (en) 2002-04-11
ATE541860T1 (en) 2012-02-15
EP1322383B9 (en) 2006-09-06
AU2001296545A1 (en) 2002-04-15
WO2002028905A3 (en) 2002-06-20
EP1326896B1 (en) 2010-11-24
AU2002211366A1 (en) 2002-04-15
US20100172912A1 (en) 2010-07-08
CA2424296A1 (en) 2002-04-11
US7445780B2 (en) 2008-11-04
US7611708B2 (en) 2009-11-03
EP1322383B1 (en) 2006-05-24
JP2009019046A (en) 2009-01-29
WO2002028481A9 (en) 2003-07-03
JP2008074870A (en) 2008-04-03
US8088383B2 (en) 2012-01-03
WO2002028904A3 (en) 2003-02-06
DE60119945D1 (en) 2006-06-29
EP1717251A3 (en) 2007-11-07
PT1326896E (en) 2011-03-03
US20110033456A1 (en) 2011-02-10
EP1326896A2 (en) 2003-07-16
ES2357051T3 (en) 2011-04-15
DE60143535D1 (en) 2011-01-05
US20080075727A1 (en) 2008-03-27
EP1322383A2 (en) 2003-07-02
WO2002028480A2 (en) 2002-04-11
US20040109857A1 (en) 2004-06-10
JP4838831B2 (en) 2011-12-14

Similar Documents

Publication Publication Date Title
WO2002028480A3 (en) Methods of therapy for b-cell malignancies
WO2005044855A3 (en) Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
WO2005044304A3 (en) Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
WO2005044854A3 (en) Antagonist anti-cd40 monoclonal antibodies and methods for their use
AU2190997A (en) Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation
EP1680141B8 (en) Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
WO2005044307A3 (en) Methods of therapy for b cell-related cancers
WO2000020864A8 (en) Immunotherapy of b cell involvement in progression of solid, nonlymphoid tumors
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
AU8867501A (en) Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
JP2004500325A5 (en)
AU3386100A (en) Anti-tnfalpha antibodies in therapy of asthma
TR200103432T2 (en) Blocking monoclonal VLA-1 antibody and its use in the treatment of inflammatory diseases.
WO2004019886A3 (en) Methods for up-regulating antigen expression in tumors
AU2003215381A1 (en) EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
EP2641611A3 (en) Combination therapy
WO2004018519A3 (en) Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor
RU2002103808A (en) METHOD FOR TREATING PAIN SYNDROME IN ONCOLOGIC PATIENTS
AU2001255537A1 (en) Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
WO2004019991A3 (en) Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
CY1114654T1 (en) ANTI-CD40 MONOCLONIC ANTIBODIES ANTI-COMPONENTS AND METHODS FOR USE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10380223

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002532304

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2424749

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001977428

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001977428

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGE 30, DESCRIPTION, REPLACED BY CORRECT PAGE 30 INTERNATIONAL SEARCH REPORT ADDED (5 PAGES)

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001977428

Country of ref document: EP